A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

  • End date
    Sep 1, 2027
  • participants needed
  • sponsor
    Daiichi Sankyo, Inc.
Updated on 10 September 2021


Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.


This study will examine trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive primary BC who have residual invasive disease in breast or axillary lymph nodes with higher risk of recurrence, which includes patients who were inoperable at disease presentation or had pathological node-positive status after neoadjuvant therapy.

The primary objective is to compare invasive disease-free survival (IDFS) between T-DXd and T-DM1 treatment arms in this population. The key secondary objective of the study is to evaluate disease-free survival (DFS).

Condition HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-Positive Primary Breast Cancer
Treatment T-DM1, DS-8201a
Clinical Study IdentifierNCT04622319
SponsorDaiichi Sankyo, Inc.
Last Modified on10 September 2021


Yes No Not Sure

Inclusion Criteria

Adults 18 years old (local regulatory requirements will apply if the legal age of consent for study participation is >18 years old)
Pathologically documented HER2-positive breast cancer (BC)
HER2-positive expression defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) confirmed prior to study randomization
Histologically confirmed invasive breast carcinoma
Clinical stage at disease presentation: T1-4, N0-3, M0; patients presenting with T1N0 tumors are not eligible
Pathologic evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes following completion of neoadjuvant therapy meeting one of the following high-risk criteria
Inoperable breast cancer at presentation (prior to neoadjuvant therapy), defined as clinical stages T4, N0-3, M0 or T1-3, N2-3, M0
Operable at presentation, defined as clinical stages T1-3,N0-1,M0, with axillary node positive disease (ypN1-3) following neoadjuvant therapy
Completion of neoadjuvant systemic chemotherapy, including taxane and HER2-directed treatment prior to surgery
Systemic therapy must consist of at least 6 cycles of chemotherapy with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab ( pertuzumab) and at least 9 weeks of taxane based chemotherapy. Patients may have received an anthracycline as part of neoadjuvant therapy in addition to taxane chemotherapy
Adequate excision as confirmed per medical records: surgical removal of all clinically evident disease in the breast and lymph nodes
An interval of no more than 12 weeks between the date of last surgery and the date of randomization
Known hormone receptor (HR) status, per local laboratory assessment, as defined by ASCO-CAP guidelines (1%): HR positive status defined by either positive estrogen receptor (ER) and/or positive progesterone receptor (PR) status. HR-negative status defined by both known negative ER and known negative PR
Left ventricular ejection fraction (LVEF) 50% within 28 days prior to randomization
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening
Has adequate organ function within 14 days before randomization

Exclusion Criteria

Stage IV (metastatic) BC
History of any prior (ipsi- or contralateral) breast cancer except lobular carcinoma in situ (LCIS)
Evidence of clinically evident gross residual or recurrent disease following neoadjuvant therapy and surgery
Prior treatment with T-DXd, T-DM1 or other anti-HER2 antibody-drug conjugate (ADC)
History of exposure to the following cumulative doses of anthracyclines
Doxorubicin > 240 mg/m^2
Epirubicin or Liposomal Doxorubicin-Hydrochloride > 480 mg/m^2
For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m^2
History of other malignancy within the last 5 years except for appropriately treated CIS of the cervix, nonmelanoma skin carcinoma, Stage I melanoma skin carcinoma, Stage I uterine cancer, or other appropriately treated non-breast malignancies
History of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids and/or has ILD/pneumonitis noted on computed tomography (CT) scan of the chest at Screening (asymptomatic interstitial changes confined to recent radiation therapy fields are not excluded)
Known pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within three months prior to randomization, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease)
Any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (eg, Rheumatoid arthritis, Sjogren's, sarcoidosis, etc.), or prior lobectomy or pneumonectomy
Medical history of myocardial infarction (MI) within 6 months before randomization, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), troponin levels consistent with MI as defined according to the manufacturer 28 days prior to randomization
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note